Recruiting
Phase 2

Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1

Sponsor:

Centre Hospitalier Universitaire de Nice

Code:

NCT06222827

Conditions

Facioscapulohumeral Muscular Dystrophy 1

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Satralizumab Prefilled Syringe

Placebo Comparator

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information